Chester County News and Community Website
PLYMOUTH MEETING, PA — A study published in the February 2026 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that incorporating prostate-specific membrane antigen PET/CT scans into evaluation …
Study Finds PSMA PET/CT Scans May Guide Treatment After Prostate Cancer Recurrence Read More
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without chemotherapy experienced a sharply …
Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …
FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the commercial launch of its Barrigel™ rectal spacer in Japan, marking a significant step in the company’s international expansion strategy. The …
Teleflex Launches Barrigel™ Rectal Spacer in Japan Following Regulatory Approval Read More PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer. …
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives Read More WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has introduced two major initiatives during Men’s Health Month to highlight the challenges men face with benign prostatic hyperplasia (BPH) and the importance …
Teleflex Launches Awareness Initiatives for Men’s Health Month Read More PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project aimed at improving the management of side effects caused …
NCCN Funds Research to Address Side Effects of PARP Inhibitors in Prostate Cancer Treatment Read More PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project aimed at improving management of side effects caused by poly …
NCCN Funds Research to Address Side Effects of PARPi Treatment in Prostate Cancer Read More